Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks of follow-up among people living with HIV (PLHIV) and high-risk Close Contacts (CC) of adults with Drug Susceptible (DS) or Rifampin Resistant (RR) TB.
Phase:
PHASE3
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Elizabeth Glaser Pediatric AIDS Foundation US Department of State